Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 2
1990 7
1991 2
1992 12
1993 16
1994 11
1995 9
1996 10
1997 10
1998 9
1999 2
2000 13
2001 7
2002 9
2003 14
2004 10
2005 10
2006 21
2007 22
2008 20
2009 13
2010 15
2011 21
2012 21
2013 24
2014 26
2015 27
2016 34
2017 28
2018 30
2019 36
2020 32
2021 30
2022 28
2023 21
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

552 results

Results by year

Filters applied: . Clear all
Page 1
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, Chevreau C, Tannir NM, Oudard S, McDermott DF, Laguerre B, Hammers HJ, Barthelemy P, Plimack ER, Borchiellini D, Gross-Goupil M, Jiang R, Lee CW, de Silva H, Rini BI, Escudier B, Albigès L. Carril-Ajuria L, et al. Among authors: motzer rj. Eur J Cancer. 2024 Apr 8;204:114048. doi: 10.1016/j.ejca.2024.114048. Online ahead of print. Eur J Cancer. 2024. PMID: 38653033
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suárez C, Porta C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, George S, Scheffold C, Wang P, Fedorov V, Motzer RJ, Choueiri TK. Powles T, et al. Among authors: motzer rj. ESMO Open. 2024 Apr 19;9(5):102994. doi: 10.1016/j.esmoop.2024.102994. Online ahead of print. ESMO Open. 2024. PMID: 38642472 Free PMC article.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T. Motzer RJ, et al. Eur Urol. 2024 Apr 5:S0302-2838(24)02234-6. doi: 10.1016/j.eururo.2024.03.015. Online ahead of print. Eur Urol. 2024. PMID: 38582713 Free article.
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM, Labaki C, Jammihal TR, Xie W, Sun M, Shah V, Saad E, Kane MH, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer RJ, Powles T, Rini BI, Albiges L, Pal SK, McGregor BA, McKay RR, Signoretti S, Van Allen EM, Shukla SA, Choueiri TK, Braun DA. Saliby RM, et al. Among authors: motzer rj. Cancer Cell. 2024 Apr 4:S1535-6108(24)00087-4. doi: 10.1016/j.ccell.2024.03.002. Online ahead of print. Cancer Cell. 2024. PMID: 38579722
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. Motzer RJ, et al. J Natl Compr Canc Netw. 2024 Feb;22(1):4-16. doi: 10.6004/jnccn.2024.0008. J Natl Compr Canc Netw. 2024. PMID: 38394781
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.
Elkrief A, Waters NR, Smith N, Dai A, Slingerland J, Aleynick N, Febles B, Gogia P, Socci ND, Lumish M, Giardina PA, Chaft JE, Eng J, Motzer RJ, Mendelsohn RB, Markey KA, Zhuang M, Li Y, Yang Z, Hollmann TJ, Rudin CM, van den Brink MRM, Shia J, DeWolf S, Schoenfeld AJ, Hellmann MD, Babady NE, Faleck DM, Peled JU. Elkrief A, et al. Among authors: motzer rj. Cancer Immunol Res. 2024 Mar 4;12(3):308-321. doi: 10.1158/2326-6066.CIR-23-0498. Cancer Immunol Res. 2024. PMID: 38108398
552 results